4//SEC Filing
Martin Michael Robert 4
Accession 0001628280-21-019048
CIK 0001600620other
Filed
Sep 21, 8:00 PM ET
Accepted
Sep 22, 4:31 PM ET
Size
23.3 KB
Accession
0001628280-21-019048
Insider Transaction Report
Form 4
Martin Michael Robert
Chief Business Officer
Transactions
- Sale
Common Shares
2021-09-21$24.02/sh−87,500$2,101,750→ 176,861 total - Exercise/Conversion
Option Grant (right to buy)
2021-09-21−70,000→ 0 totalExercise: $6.06Exp: 2029-01-29→ Common Stock (70,000 underlying) - Exercise/Conversion
Common Stock
2021-09-20$5.30/sh+28,500$151,050→ 205,361 total - Exercise/Conversion
Common Stock
2021-09-21$5.30/sh+7,500$39,750→ 184,361 total - Exercise/Conversion
Common Stock
2021-09-21$18.38/sh+10,000$183,800→ 264,361 total - Sale
Common Shares
2021-09-20$21.71/sh−12,500$271,375→ 192,861 total - Sale
Common Shares
2021-09-20$21.60/sh−16,000$345,600→ 176,861 total - Exercise/Conversion
Common Stock
2021-09-21$6.06/sh+70,000$424,200→ 254,361 total - Exercise/Conversion
Option Grant (right to buy)
2021-09-20$5.30/sh−28,500$151,050→ 7,500 totalExercise: $5.30Exp: 2028-02-01→ Common Stock (28,500 underlying) - Exercise/Conversion
Option Grant (right to buy)
2021-09-21−7,500→ 0 totalExercise: $5.30Exp: 2028-02-01→ Common Stock (7,500 underlying) - Exercise/Conversion
Option Grant (right to buy)
2021-09-21−10,000→ 56,900 totalExercise: $18.38Exp: 2030-01-28→ Common Stock (10,000 underlying)
Footnotes (8)
- [F1]Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.70 to $21.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in connection with a divorce settlement agreement.
- [F5]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.56 to $21.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F6]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.90 to $24.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F7]The shares subject to the option vest in thirty-six equal monthly installments from the grant date.
- [F8]The shares subject to the option vest in twenty-four equal monthly installments from the grant date.
Documents
Issuer
Aurinia Pharmaceuticals Inc.
CIK 0001600620
Entity typeother
Related Parties
1- filerCIK 0001837647
Filing Metadata
- Form type
- 4
- Filed
- Sep 21, 8:00 PM ET
- Accepted
- Sep 22, 4:31 PM ET
- Size
- 23.3 KB